Daiichi Sankyo Plans Growth In Mid-term Management Plan Despite Olmetec Patent Expiry
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo President Joji Nakayama announced at a medium term management plan briefing March 22 that the company aims to grow 4% a year in the Japanese market between 2013 and 2017, hoping to reach sales revenues of ¥630 billion in 2017.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.